168 related articles for article (PubMed ID: 23183425)
21. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
22. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
Gauchan D; Shaaban H; Gedeon D; Maroules M
Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
[No Abstract] [Full Text] [Related]
23. Eltrombopag and serum of a different hue.
Cardamone D; Milone MC; Glaser L; Frey NV; Kricka LJ
Arch Pathol Lab Med; 2013 Sep; 137(9):1175. PubMed ID: 23991726
[No Abstract] [Full Text] [Related]
24. Thrombopoietin-receptor agonists for immune thrombocytopenia.
Jansen AJ; Swart RM; te Boekhorst PA
N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
[No Abstract] [Full Text] [Related]
25. Thrombopoietin-receptor agonists in children with immune thrombocytopenia.
Neunert CE; Grace RF
Lancet; 2015 Oct; 386(10004):1606-9. PubMed ID: 26231462
[No Abstract] [Full Text] [Related]
26. [Thrombopoietin receptor agonist arouses new hope].
Häckel A
MMW Fortschr Med; 2016 Apr; 158(7):73. PubMed ID: 27071600
[No Abstract] [Full Text] [Related]
27. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
[No Abstract] [Full Text] [Related]
28. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
29. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
30. Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
Carrabba M; Barcellini W; Fabio G
J Clin Immunol; 2016 Jul; 36(5):434-6. PubMed ID: 27072856
[No Abstract] [Full Text] [Related]
31. Concerning survival signal for eltrombopag in MDS/AML.
Tao D; Prasad V
Leuk Lymphoma; 2020 Apr; 61(4):1002-1003. PubMed ID: 31786967
[No Abstract] [Full Text] [Related]
32. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
Cela I; Miller IJ; Katz RS; Rizman A; Shammo JM
Clin Adv Hematol Oncol; 2010 Nov; 8(11):806-9. PubMed ID: 21326158
[No Abstract] [Full Text] [Related]
33. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
Baker JE; Su J; Koprowski S; Dhanasekaran A; Aufderheide TP; Gross GJ
J Pharmacol Exp Ther; 2015 Mar; 352(3):429-37. PubMed ID: 25512369
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.
Frey N; Jang JH; Szer J; Illés Á; Kim HJ; Ram R; Chong BH; Rowe JM; Borisenkova E; Liesveld J; Winer ES; Cherfi A; Aslanis V; Ghaznawi F; Strickland S
Lancet Haematol; 2019 Mar; 6(3):e122-e131. PubMed ID: 30704923
[TBL] [Abstract][Full Text] [Related]
36. Immune thrombocytopenic purpura--from agony to agonist.
Schwartz RS
N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
[No Abstract] [Full Text] [Related]
37. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Pathak S; Roth M; Verma A; Steidl U
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
[TBL] [Abstract][Full Text] [Related]
38. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
39. Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia.
Trautmann K; Jakob C; von Grünhagen U; Schleyer E; Brümmendorf TH; Siegert G; Ehninger G; Platzbecker U
Thromb Haemost; 2012 Aug; 108(2):397-8. PubMed ID: 22739569
[No Abstract] [Full Text] [Related]
40. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
Mavroudi I; Pyrovolaki K; Pavlaki K; Kozana A; Psyllaki M; Kalpadakis C; Pontikoglou C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):323-8. PubMed ID: 20688394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
